Research programme: cancer therapeutics - BeiGeneAlternative Names: BGB-108; BGB-A425; Brodomain containing protein 4 inhibitors - BeiGene; EGFR T790 mutation inhibitors - BeiGene; iOnc monoclonal antibody - BeiGene; iONC small molecule therapeutic - BeiGene; KRAS protein inhibitors - BeiGene; PD-1 monoclonal antibody - BeiGene; PD-L1 monoclonal antibody - BeiGene; Tim-3 antibody
Latest Information Update: 18 Nov 2014
At a glance
- Originator BeiGene
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action BRD4-protein-inhibitors; CD274 antigen modulators; Epidermal growth factor inhibitors; HAVCR2 protein modulators; Immunomodulators; KRAS protein inhibitors; PDCD 1 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Nov 2014 Preclinical trials in Cancer in China (Parenteral)
- 14 Nov 2014 Preclinical trials in Cancer in China (unspecified route)